NIH R01 · 2024
Targeting Nuclear HSF1 as a Novel Anti-HCMV Strategy
Project Summary Human cytomegalovirus (HCMV) infects the majority of people in the world and can cause serious disease in immunocompromised patients and neonates. The virus establishes life-long latency in bone marrow cells and disseminates to peripheral organs in quiescently infected monocytes. Antiviral therapy delays virus replication, but does not eliminate infected cells. Virus rebound, resistance, and drug toxicity complicate treatment and create a strong demand for improved therapeutics. We advocate that the suppression of HCMV replication must be in combination with the killing of infected monocytes. We found that HCMV infection of fibroblasts and monocytes rapidly stimulated the…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.